<i>CYP2A6</i> and <i>ERCC1</i> polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

Park, S R,Kong, S-Y,Nam, B-H,Choi, I J,Kim, C G,Lee, J Y,Cho, S J,Kim, Y W,Ryu, K W,Lee, J H,Rhee, J,Park, Y-I,Kim, N K Nature Publishing Group 2011 The British journal of cancer Vol.104 No.7

<P><B>Background:</B></P><P>We evaluated the association between polymorphisms of cytochrome P450 2A6 (<I>CYP2A6</I>)/excision repair cross-complementation group 1 (<I>ERCC1</I>)/X-ray repair cross-complementing group 1(<I>XRCC1</I>) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin.</P><P><B>Methods:</B></P><P>Among MGC patients (<I>n</I>=108), who received S-1 (40 mg m<SUP>−2</SUP> b.i.d., days 1–14) and cisplatin (60 mg m<SUP>−2</SUP>, day 1) every 3 weeks, we analysed the wild-type allele (<I>W</I>) and variants (<I>V</I>) of <I>CYP2A6</I> (<I>*4</I>, <I>*7, *9, *10</I>), and the polymorphisms of <I>ERCC1</I> (rs11615, rs3212986) and <I>XRCC1</I> (rs25487).</P><P><B>Results:</B></P><P>Patients having fewer <I>CYP2A6</I> variants had better response rates (<I>W</I>/<I>W vs W</I>/<I>V</I> other than <I>*1/*4 vs V</I>/<I>V</I> or <I>*1/*4</I>=66.7 <I>vs</I> 58.3 <I>vs</I> 32.3% <I>P</I>=0.008), time to progression (TTP) (7.2 <I>vs</I> 6.1 <I>vs</I> 3.5 months, <I>P</I>=0.021), and overall survival (23.2 <I>vs</I> 15.4 <I>vs</I> 12.0 months, <I>P</I>=0.004). <I>ERCC1 19442C</I>><I>A</I> (rs3212986) was also associated with response rate (<I>C/C</I>, 46.7% <I>vs C/A</I>, 55.3% <I>vs A/A</I>, 87.5%) (<I>P</I>=0.048) and TTP (4.4 <I>vs</I> 7.6 <I>vs</I> 7.9 months) (<I>P</I>=0.012). Patients carrying both risk genotypes of <I>CYP2A6</I> (<I>V</I>/<I>V</I> or <I>1/*4</I>) and <I>ERCC1 19442C</I>><I>A</I> (<I>C/C</I>) <I>vs</I> those carrying none showed an adjusted odds ratio of 0.113 (<I>P</I>=0.004) for response, and adjusted hazard ratios of 3.748 (<I>P</I>=0.0001) for TTP and 2.961 (<I>P</I>=0.006) for death.</P><P><B>Conclusion:</B></P><P>Polymorphisms of <I>CYP2A6</I> and <I>ERCC1 19442C</I>><I>A</I> correlated with the efficacy of S-1/cisplatin.</P>

On quasi-class A contractions

Duggal, B.P.,Jeon, I.H.,Kim, I.H. Elsevier 2012 Linear algebra and its applications Vol.436 No.9

<P><B>Abstract</B></P><P>Let QA denote the class of bounded linear Hilbert space operators <I>T</I> which satisfy the operator inequality <SUP>T∗</SUP>|<SUP>T2</SUP>|T⩾<SUP>T∗</SUP>|T<SUP>|2</SUP>T. It is proved that if T∈QA is a contraction, then either <I>T</I> has a nontrivial invariant subspace or <I>T</I> is a proper contraction and the nonnegative operator D=<SUP>T∗</SUP>(|<SUP>T2</SUP>|-|T<SUP>|2</SUP>)T is strongly stable. It is shown that if T∈QA is a contraction with Hilbert–Schmidt defect operator such that <SUP>T-1</SUP>(0)⊆<SUP><SUP>T∗</SUP>-1</SUP>(0), then <I>T</I> is completely non–normal if and only if T∈<SUB>C10</SUB>, and a commutativity theorem is proved for contractions T∈QA. Let <SUB>Tu</SUB> and <SUB>Tc</SUB> denote the unitary part and the cnu part of a contraction <I>T</I>, respectively. We prove that if A=<SUB>Au</SUB>⊕<SUB>Ac</SUB> and B=<SUB>Bu</SUB>⊕<SUB>Bc</SUB> are QA-contractions such that <SUB>μ<SUB>Ac</SUB></SUB><∞, then <I>A</I> and <I>B</I> are quasi-similar if and only <SUB>Au</SUB> and <SUB>Bu</SUB> are unitarily equivalent and <SUB>Ac</SUB> and <SUB>Bc</SUB> are quasi-similar.</P>

200 GeV/핵자 유황이온과 핵건판핵의 충돌에 의해 생성된 헬륨 파쇄핵의 극한파쇄 연구

김동철,송진섭,윤천실,정성헌,박인곤,김종오,김철수,김태연,이승희,조재희,천병구,김재률,김준원,김태익,박명렬,장한일,임인택 慶尙大學校 기초과학연구소 1992 基礎科學硏究所報 Vol.8 No.-

고에너지 중이온 원자핵과 핵건판의 충돌에서, 200GeV/핵자 유황이온에 의해 생성된 파쇄 헬륨핵(Z=2)의 실험실계의 방출각 분포는 표적핵에 무관한 회귀공식. dN=exp[a+k exp(η-y_b)]d[exp(η-y_b)]로 잘 표현된다. 여기에서 의사신속도 η=-ln[tan(θ/2)]이고, y_b는 실험실계의 입사입자(^32S)의 신속도이다. 이 공식에 의한 적합에서 k=-0.057±0.008로 얻어진다. 즉, 핵건판과 고에너지 중이온의 충돌에서 파쇄 헬륨핵의 exp(η-y_b)의 분포는 "극한파쇄" 현상을 잘 설명하고 있다. The angular distribution of emission angle θ of helium (Z=2) produced in the collisions of incident particles of 200 GeV/nucleon ^32S in nuclear emulsion is well expressed by dN=exp[a+k exp(η-y_b)]d[exp(η-y_b)] where the pseudorapidity is η=-ln[tan(θ/2)], the laboratory system primary rapidity is y_b, and k=-0.057+0.008. The shape of this frequency of occurrence distributions in terms of exp(η-y_b) attests to the validity of the concept of "limiting fragmentation" for helium projectile fragments produced in the projectile fragmentation regions of heavy ion collisions in nuclear emulsion.

V994 Herculis: the multiple system with a quadruple-lined spectrum and a double eclipsing feature

Lee, C.-U.,Kim, S.-L.,Lee, J. W.,Kim, C.-H.,Jeon, Y.-B.,Kim, H.-I.,Yoon, J.-N.,Humphrey, A. Blackwell Publishing Ltd 2008 MONTHLY NOTICES- ROYAL ASTRONOMICAL SOCIETY Vol.389 No.4

<P>ABSTRACT</P><P>We report the discovery of a multiple system with a quadruple-lined spectrum and a double eclipsing feature. Our photometric and high-resolution spectroscopic data show that V994 Herculis (V994 Her; ADS 11373 AB) is composed of two pairs of double-lined eclipsing binaries, which we designate as A and B. System A consists of a B8V+A0V binary with an orbital period of 2.083 264 d and system B of a A2V+A4V binary with 1.420 033 d. Our light curves show that both of them have a detached binary configuration. We derive masses and radii of four components (Aa, Ab, Ba and Bb) from the synthetic analyses of light curves and radial velocity curves. The masses of systems A and B are <I>M</I><SUB>Aa</SUB>= 2.83 ± 0.20 M<SUB>⊙</SUB>, <I>M</I><SUB>Ab</SUB>= 2.30 ± 0.16 M<SUB>⊙</SUB>, <I>M</I><SUB>Ba</SUB>= 1.87 ± 0.12 M<SUB>⊙</SUB> and <I>M</I><SUB>Bb</SUB>= 1.86 ± 0.12 M<SUB>⊙</SUB>, with radii <I>R</I><SUB>Aa</SUB>= 2.15 ± 0.05 R<SUB>⊙</SUB>, <I>R</I><SUB>Ab</SUB>= 1.71 ± 0.04 R<SUB>⊙</SUB>, <I>R</I><SUB>Ba</SUB>= 1.59 ± 0.08 R<SUB>⊙</SUB> and <I>R</I><SUB>Bb</SUB>= 1.50 ± 0.08 R<SUB>⊙</SUB>, respectively. These masses and radii are well consistent with the empirical relation for double-lined eclipsing binaries.</P>

14.6 A GeV ^28Si 중이온이 원자핵건판내에서 발생시킨 핵반응에서 생성된 2차입자의 발생각 분포

김종오,김태연,남신우,신택수,우종관,이세병,임계엽,장세덕,조재희,천병구,임인택,김기영 慶尙大學校 기초과학연구소 1990 基礎科學硏究所報 Vol.6 No.-

14.6A GeV^28Si 중이온이 원자핵 건판내에서 발생시킨 N_h=1인 핵반응에서 생성된 47개의 파쇄 α 입자와 537개의 단일하전 2차입자의 발생각들을 측정하여 변수 exp(γ-η_b)의 포괄적 분포를 회귀함수 dN=exp[a+χ{exp(γ-η_b)d{exp(γ-η_b)}로 적합시켰다. 여기서 의사신속도 γ=arctanh(cosθ)=-ln tan(θ/2)이고, 입사 중이온의 신속도 η_b=3.445이다. 그 적합결과 파쇄 α입자의 경우 χ=-0.052±0.011이고, 파쇄 p입자의 경우 χ=-0.141±0.015이었다. For LS emission angles of 47 α fragments and 537 single-charged shower particles, produced by the N_h (the number of heavyprongs)=1 interactions of 14.6 A GeV^28Si nuclei in the nuclear emulsion, the distribution of the parameter exp(γ-η_b) is well expressed by dN=exp[a+χ{exp(γ-η_b)d{exp(γ-η_b)}with χ=-0.052±0.011 for αfragments and χ=-0.141±0.015 for p 'fragments', where the pseudorapidity of secondaries γ=arctanh(cosθ)=-ln tan(θ/2) and the rapidity of incident heavy ions, η_b=3.445.

Polymorphisms in the neurokinin-2 receptor gene are associated with angiotensin-converting enzyme inhibitor-induced cough

Kim, T.-B.,Oh, S.-Y.,Park, H.-K.,Jeon, S.-G.,Chang, Y.-S.,Lee, K.-Y.,Cho, Y. S.,Chae, I.-H.,Kim, Y.-K.,Cho, S.-H.,Moon, H.-B.,Min, K.-U.,Kim, Y.-Y. Blackwell Publishing Ltd 2009 Journal of clinical pharmacy and therapeutics Vol.34 No.4

<P>Summary</P><P>Background and objective: </P><P>Treatment with angiotensin-converting enzyme (ACE) inhibitors can induce chronic cough in many patients. Genetic variations in the neurokinin 2 receptor gene (NK2R) are significantly associated with cough sensitivity to capsaicin.</P><P>Methods: </P><P>This study assessed the relationship between genetic polymorphisms in the NK2R gene and chronic cough in 91 patients taking ACE inhibitors. Patients included in the study did not have chest abnormalities, postnasal drip, gastroesophageal reflux or a recent history of upper respiratory infection.</P><P>Results: </P><P>We detected two single nucleotide polymorphisms in the NK2R gene (i.e., Gly231Glu and Arg375His). The allelic frequencies at amino acid 231 were 36·3% for Gly/Gly, 49·5% for Gly/Glu and 14·3% for Glu/Glu. The allelic frequencies at amino acid 375 were 74·7% for Arg/Arg, 24·2% for Arg/His and 1·1% for His/His. The prevalence of chronic cough in patients with the amino acid 231 genotype was 33·3% in Gly/Gly homozygotes, 24·4% in Gly/Glu heterozygotes and 0% in Glu/Glu homozygotes. There was a statistically significant association between chronic cough and the Glu/Glu allele (<I>P</I> = 0·028) when the data were analyzed with a recessive model. In addition, there was a significant inverse linear association between the number of Glu231 alleles and ACE inhibitor-related cough (<I>P </I>=<I> </I>0·026). The prevalence of chronic cough in patients with the amino acid 375 genotype was 22·1% in Arg/Arg homozygotes, 31·8% in Arg/His heterozygotes and 0% in His/His homozygotes, although none of these association were statistically significant.</P><P>Conclusion: </P><P>Our findings indicate that the Gly231Glu polymorphism is associated with a lower prevalence of ACE inhibitor-related cough.</P>

Effect of Carbohydrate Sources in Phase I and Phase II Pig Starter Diets

Kim, I.B.,Allee, G.L. Asian Australasian Association of Animal Productio 2001 Animal Bioscience Vol.14 No.10

Previous research in our laboratory has demonstrated the importance of lactose in phase I and II pig starter diets. Two experiments were conducted to evaluate the use of a carbohydrate by-product (food by-products) as a replacement for lactose. In Exp. I, 120 weaned pigs ($14{\pm}2d$ and 5.65kg) were allotted in a randomized complete block design (RCBD) to 10 replications with four pigs per pen. This experiment evaluated three carbohydrate sources (lactose, carbohydrate by-product, and 50-50 blend of the carbohydrate by-product and lactose). The carbohydrate sources were added at 26% in the phase I diets and 15% in the phase II diets. Phase I diets contained 7.5% spray dried plasma protein (SDP). The phase I diets were fed from d 0 to 14 and the phase II diets from d 15 to 28. There were no significant differences between carbohydrate sources on pig performance in phase I. However, during phase II pigs fed the diet with lactose had an improved gain/feed ratio (G/F) (p=0.06) compared to pigs fed the carbohydrate by-product. For the entire 28 d trial ADG, ADFI and G/F were similar for the 50-50 blend and those fed lactose. Total replacement of lactose with the carbohydrate byproduct resulted in a reduced G/F (p=0.09). Exp. 2 used 100 weaned pigs ($17{\pm}2d$ and 4.75kg) with five replications with five pigs per pen. This experiment evaluated four carbohydrate treatments (lactose, carbohydrate by-products, 50-50 blend, and corn). All phase I diets contained 3.5% SDP with the carbohydrate sources included at 15%, and were fed d 0 to 14. The phase II diets contained 7.5% of the carbohydrate sources and were fed d 15 to 27. A common phase III diet was fed d 28 to 42. During all phases pigs fed com tended to have a lower ADG than pigs fed the other carbohydrate sources with the 50-50 blend resulting in the highest ADG. The results of both experiments suggest that this carbohydrate by-product can replace at least 50% of the lactose in phase I and phase II pig starter diets.

1.88A GeV ^56Fe 중이온에 의해 원자핵건판 내에서 회절들뜸 및 준회절들뜸 기구로 생긴 다중발생

김종오,김태연,천병구,박인곤,송진섭,윤천실,박상렬,이경언,김재률,김태익,박명렬,임인택,장한일,박복남 慶尙大學校 기초과학연구소 1990 基礎科學硏究所報 Vol.6 No.-

원자핵건판 내에서 1.88A GeV의 에너지를 갖는 ^56Fe 중이온(heavy ion)의 평균자유행로는 비적추적법(along-the-track scanning method)을 사용하여 8.01±0.27㎝로 측정되었다. ^56Fe 주이온에 의한 회절들뜸반응을 KHP 판정법으로 찾아내었으며, 회절들뜸반응에 대한 평균자유행로는 0.86±0.10m로 측정되었다. 입사중이온의 정지계 내에서 ^56Fe 중이온에 의한 80개의 회절들뜸 및 준회절들뜸반응에 대한 알파입자와 단일하전 입자의 의사신속도 분포는 각각 (γ_a-η_b)_max=3.31, (γ_a-η_b)_max=2.30에서 최대값을 갖는 가우스분포함수 형태를 이루었다. By employing the method of along-the -track scanning. the mean free path of inelastic collisions for 1.8A GeV^56Fe heavy ion in nuclear emulsion is measured to be 8.01±0.27㎝. "Diffractive Excitation" events are identified by using the KHP method and the mean free path of diffractive excitation is measured to be 0.86±0.10m. The distributions of pseudorapidities of alpha and singly-charged fragments for diffractive excitation of 1.88A GeV ^Fe heavy ion are well fitted by Gaussian distribution function with peaks having (γ_a-η_b)_max=3.30 and (γ_p-η_b)_max=2.24.

Harmless R-parity violation from Z_12-I compactification of E₈xE₈^' heterotic string

Kim, I.W.,Kim, J.E.,Kyae, B. North-Holland Pub. Co 2007 Physics letters. Section B Vol.647 No.4

In a recent Z<SUB>12-I</SUB> orbifold model, an approximate Z<SUB>2</SUB> symmetry which forbids the baryon number violating operators up to sufficiently high orders is found. The dimension-4 ΔB<>0 operators of the MSSM fields occur at dimension 10. The effective dimension-5 ΔB<>0 operators derived from these are harmless if some VEVs of neutral singlets are O(110) times the string scale. The main reason for forbidding these ΔB<>0 operators up to such a high order is the large order N=12 of Z<SUB>N</SUB> since the H-momentum rule is (-1,1,1) mod (12,3,12). For a lower order N<12, the ΔB<>0 operators would appear at lower dimensions.

Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures

Kim, E-K,Seo, H-S,Chae, M-J,Jeon, I-S,Song, B-Y,Park, Y-J,Ahn, H M,Yun, C-O,Kang, C-Y Macmillan Publishers Limited 2014 Gene therapy Vol.21 No.1

For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/neu (Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the in vivo growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies.